Evidence map›Paper›PMID 21179241›Full record

ArticleMolecular vision2010

Effectiveness of topical caffeine in cataract prevention: studies with galactose cataract.

Shambhu D Varma, Svitlana Kovtun, Kavita Hegde

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Caffeine and Vision: Effects on the Eye.Turkish journal of ophthalmology · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Effects of caffeine on sleep quality and daytime functioning.Risk management and healthcare policy · 2018
    Review
  11. Effect of coffee (caffeine) against human cataract blindness.Clinical ophthalmology (Auckland, N.Z.) · 2016
    Article
  12. Article
  13. Review
  14. A simple and stable galactosemic cataract model for rats.International journal of clinical and experimental medicine · 2015
    Article
  15. Caffeine eye drops protect against UV-B cataract.Experimental eye research · 2013
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shambhu D VarmaDepartment of Ophthalmology and Visual Sciences, University Of Maryland School of Medicine, Baltimore, MD 21201, USA. svarm001@umaryland.edu
Svitlana Kovtun
Kavita Hegde
University of Mary · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe primary objective of the study was to investigate the possible inhibition of cataract formation by topical administration of caffeine using the galactosemic rat model. It was hypothesized that caffeine will do so by acting as scavenger of reactive oxygen species known to be generated under hyperglycemic conditions.

methodsCataract was induced by feeding young rats a diet containing 24% galactose for a period of 25 days. A control group of such rats was treated with a placebo eye drop preparation containing hydroxy propyl methyl cellulose as a wetting agent. In the experimental group, the rats were treated with the above preparation mixed with 72 mM caffeine.

resultsAdministration of caffeine eye drops was found to significantly inhibit the onset as well as the progress of cataract formation. By day 25 on the galactose diet, all the animals in the control group developed advanced white opacity spread over the entire area of the lens. In the caffeine group, the formation of such opacity remained strikingly inhibited. The lenses remained largely transparent. The transparency data paralleled the higher concentration of glutathione maintained by caffeine treatment. Its levels in the placebo group were 0.8, 0.5, and 0.4 µmoles/g lens wt. on days 5, 15, and 25 against a consistent basal control value of ~3 µmoles/g over the entire period. In the caffeine group, the corresponding values were nearly 3 µmoles/g till day 15, but decreasing to ~2 µmoles/g on day 25. The levels were hence significantly higher than in the caffeine untreated group, remaining relatively closer to the basal controls. In addition, the compound was found effective in inhibiting morphological changes induced by galactose.

conclusionsMicromolar amounts of topical caffeine have been found to be significantly effective in inhibiting the formation of galactose cataract, strongly suggesting its possible usefulness against diabetic cataracts. The effects are attributed to its ability to prevent oxidative stress and consequent maintenance of tissue metabolic and transport functions, in addition to preventing the induction of apoptosis.

Indexed as

Administration, TopicalAnimalsApoptosisAqueous HumorCaffeineCataractGalactoseGlutathioneLens, CrystallineRatsCaffeineGalactoseGlutathione

Identifiers

PMID21179241
PMCPMC3002968
OpenAlexW2101059550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.